The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Journal of Surgical Oncology

Volumn 110, Issue 7, 2014, Pages 779-785

  Prada Villaverde, Arancha ^a   Esquivel, Jesus ^b   Lowy, Andrew M ^c   Markman, Maurie ^b   Chua, Terence ^d   Pelz, Joerg ^e   Baratti, Dario ^f   Baumgartner, Joel M ^c   Berri, Richard ^g   Bretcha Boix, Pedro ^h   Deraco, Marcello ^f   Flores Ayala, Guillermo ⁱ   Glehen, Olivier ^j   Gomez Portilla, Alberto ^k   González Moreno, Santiago ^l   Goodman, Martin ^m   Halkia, Evgenia ⁿ   Kusamura, Shigeki ^f   Moller, Mecker ^o   Passot, Guillaume ^j   Pocard, Marc ^p   Salti, George ^q   Sardi, Armando ^r   Senthil, Maheswari ^s   Spiliotis, John ⁿ   Torres Melero, Juan ^t   Turaga, Kiran ^u   Trout, Richard ^v   more..

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b CANCER TREATMENT CENTERS OF AMERICA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST GEORGE HOSPITAL   (Australia)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^h USP Hospital San Jaime   (Spain)

ⁱ OPD Instituto Jalisciense de Cancerologia   (Mexico)

^j CENTRE HOSPITALIER LYON SUD   (France)

^k Hospital San Jose   (Spain)

^l MD ANDERSON CANCER CENTER   (Spain)

^m TUFTS MEDICAL CENTER   (United States)

ⁿ Metaxa Cancer Memorial Hospital   (Greece)

^o UNIVERSITY OF MIAMI   (United States)

^p HÔPITAL LARIBOISIÈRE   (France)

^q UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^r MERCY MEDICAL CENTER   (United States)

^s LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^t HOSPITAL TORRECÁRDENAS   (Spain)

^u MEDICAL COLLEGE OF WISCONSIN   (United States)

^v RUTGERS UNIVERSITY   (United States)

more..

Author keywords

colorectal cancer with peritoneal carcinomatosis; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy (HIPEC)

Indexed keywords

MITOMYCIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY ASSESSMENT; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEAL SURFACE DISEASE SEVERITY SCORE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; ABDOMINAL SURGERY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FOLLOW UP; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; REGIONAL PERFUSION; SECONDARY; SURVIVAL RATE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84922329818     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23728     Document Type: Article

References (15)

1. Elias D, Quenet F, Goéré D,: Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 2012; 21: 611-623.
2. Brücher B, Piso P, Verwaal V, et al.,: Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC-overview and basic. Cancer Invest 2012; 30: 209-224.
3. Esquivel J, Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan and Korea. Cancer J 2009; 15: 249-254.
4. Esquivel J, The American Society of Peritoneal Surface Malignancies (ASPSM). Ann Surg Oncol 2011; 18: S218-S219.
5. Turaga K, Levine E, Barone R, et al.,: Consensus guidelines from the american society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2014; 21: 1501-1505.
6. Sugarbaker PH,: Peritonectomy procedures. Surg Oncol Clin N Am 2003; 12: 703-727.
7. Chua TC, Morris DL, Saxena A, et al.,: Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: A Multicenter Study. Ann Surg Oncol 2011; 18: 1560-1567.
8. Chua TC, Morris DL, Esquivel J,: Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2010; 17: 1330-1336.
9. Pelz JOW, Chua TC, Esquivel J, et al.,: Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer 2010; 10: 689.
10. Pelz JOW, Stojadinovic A, Nissan A, et al.,: Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 2009; 99: 9-15.
11. Chua TC, Esquivel J, Pelz JOW, et al.,: Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol 2012; doi: 10.1002/jso.23189
12. Cohen MS, Al-kasspooles MF, Williamson SK, et al.,: Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis In vivo ". Ann Surg Oncol 2010; 17: 296-303.
13. Votalopoulos K, Ihemelandu C, Shen P, et al.,: A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 2013; 179: 133-139.
14. Reinacer-Schick A, Schulmann K, Modest DP, et al.,: Effect of KRAS codon 13 mutations in patients with advanced colorectal cancer under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer 2012; 12: 349.
15. Gillern SM, Chua TC, Stojadinovic A, et al.,: KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. Ann J Clin Oncol 2010; 33: 456-460.